Specialty Chemicals & Gases

Tatva Chintan Pharma Chem

TATVANSESmall Cap

Live₹1,360syncing…

Specialty chemicals with phase transfer catalysts, electronics chemistry and structure-directing agents.

Market Cap

₹3.2k cr

Price

1360

1Y -8%

Direct exposure

25/100

0–100 directness

Sell / Avoid

Fundamental

37/ 100

Quality of growth, returns, cash conversion and balance sheet

Technical (TQ-100)

28/ 100

Trend, momentum, volume and relative strength composite

Valuation

38/ 100

Higher = cheaper vs peers and own history

Final composite

39/ 100

Blended decision input

Data transparency

What's real, what's pending, on this page

Real financials loaded

✓ Real / verified

· Live price, day change, market cap — NSE direct
· 1Y OHLCV, RSI(14), 50/200 DMA, 1M/3M/1Y returns, RS vs Nifty — computed from real NSE OHLCV
· Sector P/E — NSE direct
· Promoter %, pledge %, MF/FII/public split, 9-quarter history — Trendlyne
· Earnings call AI summaries — Trendlyne (where available)
· Technical (TQ-100) score — computed from real OHLCV
· Annual revenue / EBITDA / PAT / OCF / FCF / equity / assets — Trendlyne (audited annuals)

⚠ Analyst-set (qualitative)

· Segment classification + semicon directness score — analyst seed
· Bull/bear case + monitorables (curated thesis) — analyst seed
· Governance risk score (seed) — being replaced by AI-agent assessment
· Synthesized 5Y forecast removed entirely (was inaccurate)

Real financials extracted for 42 of 45 companies. See /data-sources for full provenance.

Tatva Chintan Pharma Chem · TATVA

₹1,360-8.44% over 6M

Price50 DMA200 DMA

RSI (14)

Momentum oscillator · 6M view

Volume (60D)

Fundamental score (SageOne 100)

37/ 100D

Growth 20 / Margin 15 / ROC 20 / Cash 15 / Leverage 10 / Reinvestment 8 / Accounting 7 / Governance 5 minus red flags (capped -20).

Base 45

Red flags -8

Growth quality/ 20

0.0

Rev 1Y -4.2% · 3Y CAGR -5.5%

Margin & profitability/ 15

6.1

EBITDA 20.1% · PAT 0.1%

Return on capital/ 20

3.1

ROCE 9% · ROE 0%

Cash flow quality/ 15

15.0

OCF/EBITDA 138% · FCF yield -0.6%

Leverage discipline/ 10

8.0

Net Debt/EBITDA 0.60x

Reinvestment runway/ 8

2.2

ROCE × retention proxy

Accounting quality/ 7

7.0

OCF conversion proxy

Governance/ 5

3.8

Pledge 0.0% · Risk 24/100

Red flags (2)

− Sub-threshold ROCEROCE 9% below 12% threshold-4
− Declining revenueRev 1Y -4.2%-4

✓ Computed from real Trendlyne annuals (revenue, EBITDA, PAT, OCF, equity).

Technical score (TQ-100)

28/ 100D

Computed from real 1Y OHLCV pulled from NSE direct: trend, momentum, volume, RS vs Nifty, MA cluster, mean reversion, volatility, patterns minus red flags.

Base 38

Red flags -10

Trend structure/ 20

6.8

Below 200DMA · -16% from 52W high

Momentum velocity/ 15

9.0

RSI(14) 44 · 1M 0.0%

Volume dynamics/ 15

8.3

Bucket: Small Cap

Relative strength/ 15

3.0

RS vs Nifty -18%

MA cluster/ 10

0.0

200DMA + 1Y trend confirmation

Mean-reversion runway/ 10

6.3

RSI(14) 44; ideal 50-60

Volatility profile/ 8

4.8

Bucket: Small Cap

Pattern integrity/ 7

0.0

Trend continuation proxy

Red flags (1)

− Below 200 DMALong-term trend broken-10

AI research agents

Re-classify segment exposure and re-assess governance risk by running fresh AI agents on the latest data. Results cache to data/agents.json.

Segment classifier

Maps to value-chain segments + computes 0-100 directness

Seed: Specialty Chemicals & Gases · 25/100

Governance assessor

Forensic-accounting flags + 0-100 risk score

Seed: 24/100 risk

AI thesis

Generates a fresh thesis grounded in this company's data. Wires to Anthropic when ANTHROPIC_API_KEY is set, otherwise returns a deterministic mock.

Curated thesis

Analyst-set bull, bear and monitorables · use AI thesis above for a fresh take

Niche specialty chemicals with weak near-term execution; thesis on hold.

Bull case

+Strong promoter holding
+Specialty mix
+Capacity in place

Bear case

−Weak ROCE
−Volume softness
−Technical breakdown

Key monitorables

Volume recoveryROCE trajectorySpecialty margin trend

Semiconductor exposure

How direct, how visible

Primary segment

Specialty Chemicals & Gases

All segments

Specialty Chemicals & Gases

Exposure type

Ancillary

Policy beneficiary

Possible

Import substitution

Medium / Low

Governance risk score

24/100 (lower = better)

Financial snapshot

Latest reported metrics · mock data, ready for live financials

Rev growth (1Y)

-4.2%

Rev CAGR (3Y)

-5.5%

EBITDA margin

20.1%

PAT margin

0.1%

ROCE

ROE

OCF / EBITDA

138%

Net Debt / EBITDA

0.6x

Promoter holding

76.0%

Promoter pledge

0.0%

Valuation

P/E (TTM)

93.7

Forward P/E

40.0

EV/EBITDA

42.8

EV/Sales

8.6

P/B

4.4

FCF Yield

-0.6%

Dividend Yield

0.30%

Hist. percentile

50%

Peer percentile

60%

Technicals

RSI(14)

1M return

0.0%

1Y return

-8%

From 52W high

-16%

RS vs Nifty

-18%

>200 DMA

Annual financials — real data

Extracted from Trendlyne · audited annuals · TTM + last 6 fiscal years

✓ Real

Line	TTM	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	₹477 cr	₹370 cr	₹386 cr	₹409 cr	₹438 cr	₹296 cr	₹254 cr
↳ YoY growth	+28.8%	-4.2%	-5.5%	-6.8%	+47.9%	+16.5%	—
EBITDA	₹29 cr	₹74 cr	₹60 cr	₹116 cr	₹70 cr	₹53 cr	—
↳ EBITDA margin	6.2%	20.1%	15.6%	28.5%	16.0%	17.9%	—
PAT	₹31 cr	₹0 cr	₹29 cr	₹41 cr	₹96 cr	₹51 cr	₹35 cr
↳ PAT margin	6.5%	0.1%	7.6%	9.9%	21.9%	17.3%	13.8%
OCF	₹24 cr	₹103 cr	₹24 cr	₹20 cr	₹23 cr	₹25 cr	—
↳ OCF / EBITDA	81.3%	138.2%	39.2%	17.1%	32.4%	46.4%	—
FCF (= OCF − capex)	₹-41 cr	₹-18 cr	₹-77 cr	₹-177 cr	₹2 cr	₹-16 cr	—
Total Equity	₹721 cr	₹726 cr	₹505 cr	₹469 cr	₹162 cr	₹115 cr	—
Total Assets	₹823 cr	₹815 cr	₹755 cr	₹652 cr	₹310 cr	₹245 cr	—
↳ ROE	4.3%	0.0%	5.8%	8.6%	59.3%	44.9%	—
↳ ROA	3.8%	0.0%	3.9%	6.2%	31.0%	21.0%	—

Source: Trendlyne (Standalone where Consolidated unavailable). Last refresh on real-data ingest.

Promoter pledge & shareholding history

From Trendlyne · 9 quarters · synced Invalid Date

Pledge: 0.0%

Promoter

72.0%

Mutual Funds

2.9%

FII

3.8%

Public

21.2%

Promoter holding trend

72.0

Mar

72.0

Jun

72.0

Sep

72.0

Dec

72.0

Mar

72.0

Jun

72.0

Sep

72.0

Dec

72.0

Mar

Δ:+0.0% over 9 quarters

Commentary

·Promoter rock-stable at 72%
·No pledge

Management quality

Capital allocation, debt discipline, alignment, governance composite. Computed from disclosed metrics.

Capital allocation

Sub-threshold ROCE; capital allocation needs scrutiny.

ROCE 9%, div yield 0.3%

Promoter holding

Promoter has strong skin in the game.

76.0%

Promoter pledge

No pledging — cleanest signal.

0.0%

Debt discipline

Comfortable leverage band.

Net Debt/EBITDA 0.60x

Cash conversion

Reported EBITDA reliably translates into cash.

OCF/EBITDA 138%

Governance composite

Some watchpoints; nothing disqualifying.

24/100 risk

Variant perception

What the market is pricing in versus our read, and what would invalidate the thesis.

What the market is pricing in

Steady but unspectacular execution. Multiples reflect mid-pack expectations.

What we think it's missing

Consensus appears reasonable. Look for thesis-changing catalysts (margin inflection, new customer wins, segment mix shift) rather than narrative re-rating alone.

Thesis killers

×Demand cycle softens enough to derail margin expansion

References

Wire to live data sources in production

NSE filings Screener BSE corporate filings Annual report (latest)Concall transcript (latest)Investor presentation